Skip to main content
MLYS logo

MLYS · Mineralys Therapeutics, Inc.

Track MLYS — free
$14.53 +0.00 (+0.00%)
Market Cap
$1.29B
Shares
88.56M
Volume · Nov 17 358.94K Avg daily vol (3M) 1.52M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$14.53 Open$15.16 Day$14.45–15.77 52W close$14.53–44.26 Avg vol 30d1.8M Short int7.7M · 8.7% of shares · 5.0d Short vol32% Last earningsNov 4, 2026 DataFeb 2023–Nov 2026 Filing10-Q · Nov 4

Up next

Mar 11, 2027 Est · unconfirmed · in 16 wks

Latest documents

2026
Nov 12
Investor event
Lorunderstat tracks toward December 22nd PDUFA date

Mineralis Therapeutics tracks a December 22nd PDUFA date for lorunderstat and readiness for a 2027 launch. It stated $625 million in capital, including a $500 million secured facility with $100 million drawn.

4 source passages
welcome to the Mineralis Therapeutics Session. We are progressing towards our PDUFA date, December 22nd of this year, and have progressively built out a readiness to ensure that we have a successful launch going into 2027. how to incorporate lorunderstat into their treatment paradigm. We stated in our Q3 call, $625 million in capital right now. We did the facility this summer, $500 million, pulled $100 at the close. Open the document at this passage
Nov 4
Earnings call
Lerunderstat PDUFA target date is December 22nd

Mineralis Therapeutics is preparing for potential Lerunderstat approval after its December 22nd PDUFA target date, with launch preparations advancing and $624.7 million in cash, cash equivalents, and investments funding operations into 2028.

4 source passages
We are now just weeks away from our PDUFA target date of December 22nd. Our commercial organization continues to execute against our launch preparation plans, and we are advancing through the final stages of launch readiness. We ended the quarter with cash, cash equivalents, and investments of $624.7 million as of September 30, 2026. Compared to $656.6 million as of December 31, 2025, we believe that our current cash, cash equivalents, and investments will be sufficient to fund our planned operations, including the commercial launch of Lurundrastat, into 2028. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Lorundrostat FDA target date set for December 22, 2026

Mineralys Therapeutics said the FDA accepted its lorundrostat NDA for hypertension, with a PDUFA target date of December 22, 2026.

Net loss $57.33M Diluted EPS -$0.64
Read from the MD&A section
Source passage
We submitted our NDA to the FDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs. The FDA accepted the NDA submission and provided us with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026 for lorundrostat. Open the document at this passage
Nov 4
Current report 8-K Events of Oct 29
Lorundrostat on track for December 22, 2026 PDUFA date

Mineralys said lorundrostat remains on track for a December 22, 2026 PDUFA target date. Third-quarter net loss was $57.3 million, and cash, cash equivalents and investments were $624.7 million as of September 30, 2026.

Financial results, Director or officer change, or executive pay
3 source passages
The U.S. Food and Drug Administration (FDA) continues its review of the NDA for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026. Net loss was $57.3 million for the quarter ended September 30, 2026, compared to $36.9 million for the quarter ended September 30, 2025. Cash, cash equivalents and investments were $624.7 million as of September 30, 2026, compared to $656.6 million as of December 31, 2025. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$369.97M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$101.17M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+26.1%
Year over year · more shares
Price change (1Y)
-64.4%
Trailing year
Short interest
8.7%
Latest settlement · 5.0 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. Ahead of the December 22, 2026 PDUFA date, launch preparations are on track, while Launch-HTN and Explore-OSA showed favorable blood-pressure results and long-term TRANSFORM-HTN data are scheduled for presentation. Current liquidity is expected to fund operations and the commercial launch into 2028. The company also reported higher G&A expense, a larger net loss, lower liquidity, higher interest expense, and no measurable change in the Explore-OSA apnea-hypopnea index.

Bullish
  • + Commercial launch readiness advanced with an expanded medical affairs team, a sales force in place, payer engagement, brand marketing underway, and a patient support program being finalized.
  • + New long-term efficacy and safety data from TRANSFORM-HTN are scheduled for a late-breaking presentation at the American Heart Association Scientific Sessions 2026.
  • + Current liquidity is expected to fund planned operations and the commercial launch into 2028.
  • + R&D expense decreased to $22.7 million from $31.5 million in the prior-year quarter.
Bearish
  • − Net loss increased to $57.3 million from $36.9 million in the prior-year quarter.
  • − Cash, cash equivalents, and investments declined to $624.7 million from $656.6 million at year-end 2025.
  • − Interest expense increased by $3.2 million due to the senior secured term loan entered into in June 2026.
  • − Explore-OSA produced no measurable change in the apnea-hypopnea index.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 22.9 · elevated Equity put/call 0.73
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −44%
below
Price vs 50-day avg −35%
below
RSI (14) 30
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −31%
trailing
6-month return −52%
trailing
YTD return −60%
this year
Relative strength −50%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $22 › 200d $26 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +31 funds added
Insider flow Distributing
Net -$3.0M over 90 days · 100% sells
Short interest Rising
8.68% of shares out · ▲ +3.3% MoM · 5.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
217 holders — mid 3-yr range
Squeeze score 54
elevated · 0–100
Fundamentals
Excellent
EPS growth +37%
Y/Y
Balance sheet $172.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 61%
annualized · 1-yr
Max drawdown −67%
past year
ATR 9.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−44% Bearish
Price vs 50-day avg
−35% Bearish
RSI (14)
30 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $22 › 200d $26 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +31 funds added
Insider flow Distributing
Net -$3.0M over 90 days · 100% sells
Short interest Rising
8.68% of shares out · ▲ +3.3% MoM · 5.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
217 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $15 Now $15 · 0% Range high $44
vs 200-day avg -44% vs 50-day avg -35%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MLYS
Mineralys Therapeutics, Inc.
this stock
$1.29B -60.0% — — 8.7%
VRTX
Vertex Pharmaceuticals Inc
$136.35B +18.6% +46.2% 34.6 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$98.52B +23.4% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
$87.10B +630.0% +4.3% — 8.2%
CSLLY
Csl Ltd
$65.26B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
217
% held
108.5%
Net QoQ
-3.6M sh
Top holder
Catalys Pacific, LLC
Held Float
View
Held by Funds
Fund positions
231
View
Short & Settlement
Short Interest Rising
Shares short
7.7M
Days to cover
5.0d
Change
+248.9K sh
View
Short Volume
Short vol %
32%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
1.3K
Value
$31.5K
As of
Oct 2, 2026
View
Off-Exchange
Off-exchange %
35.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$3.0M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-154.7M
EPS diluted
$-2.29
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 12, 2026
This year
25

Mineralis Therapeutics tracks a December 22nd PDUFA date for lorunderstat and readiness for a 2027 launch. It stated $625 million in capital, including a $500 million secured facility with $100 million drawn.

View
Proposed Sales
Value
$78.1K
Shares
3.5K
Filed
Oct 13, 2026
View
Exempt Offerings
Offering
$118.0M
Filed
Jun 13, 2022
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
Mineralys Therapeutics Presents N…
Published
Nov 8, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
MLYS -8.1% -30.5% -51.6% -20.1% -60.0%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY -6.4% -27.1% -50.2% -18.0% -68.5%
Key facts CIK 1933414 CUSIP 603170101 13F (30d) 218 filings 206 filers Visit website Investor relations